ControlRad Expands Patent Portfolio to 18 Granted Patents

PHILADELPHIA, PA – [March 2018] – ControlRad, Inc. announced today that it has expanded its patent portfolio to 18 patents covering their innovative radiation dose reduction technologies which dramatically reduce unnecessary radiation exposure to both patients and medical staff.

“Our IP portfolio continues to grow as we focus on key differentiated innovations,” said Guillaume Bailliard, President and CEO of ControlRad. “The portfolio includes method claims on the unique way we reduce radiation without impacting image quality and workflow, the use of an eye tracker or tablet to move semi-transparent filters, new filter designs, and even image quality algorithms.”

ControlRad is a privately held medical technology company developing a family of innovative products that dramatically reduce the amount of ionizing radiation exposure during fluoroscopically guided interventional procedures. The company is also looking to expand it portfolio with another 44 filed patents pending.

ControlRad’s products give physicians the ability to optimize the X-ray beam, producing the greatest resolution where it is needed while retaining the appropriate image quality in the periphery. Physicians can deliver the right amount of radiation to the right spot at the right time.

In a 2016 peer-reviewed published study, ControlRad’s eye-tracker technology reduced the radiation dose exposure to the patient and operators by approximately 75 percent, without interfering with the performance of the procedure. They also found that the radiation reducing technique produced a subjective enhancement of perceived visualization.

Following that demonstration, the company has pursued an ambitious program to expand the technology development across several applications and aligned with undisclosed strategic partners as they prepare to commercially launch the products.

About Radiation Risks
Fluoroscopic imaging, utilizing continuous X-ray radiation to provide real-time visualization of internal structures of the body, remains an essential component of life-saving, minimally invasive interventional procedures. In the United States, there are approximately 7,000 fixed c-arms in use by cardiologists, radiologists and vascular surgeons and 25,000 mobile c-arms utilized by orthopedic surgeons, pain management physicians, vascular surgeons, urologists, gastroenterologists, and pulmonologists. Despite a variety of precautions, physicians and medical staff using this equipment during interventional procedures are exposed to levels of radiation over time that are orders of magnitude higher than other healthcare professionals and the general public. This excessive lifetime exposure to radiation is recognized as a serious problem with well-documented health risks, including increased incidence of cataracts, stroke and disproportionate rates of atherosclerosis and possibly cancer.

About ControlRad
ControlRad, Inc. is a privately-held medical technology company developing innovative products that dramatically reduce the lifetime risk of radiation exposure from fluoroscopically guided interventional procedures (FGIP) for patients and healthcare professionals. These products are designed to improve safety without compromising image quality or workflow. This is accomplished with an integrated set of proprietary components, which optimize the X-ray beam to deliver optimal image quality in the clinically-relevant region of focus of the physician while maintaining appropriate resolution in the periphery. ControlRad is headquartered in Philadelphia and has engineering development facilities in Kfar Saba, Israel. For more information, visit